Journal of Urgent Care Medicine

RSV Vaccine Shows High Effectiveness In Infants

In a study of 31,900 healthy term infants at Kaiser Permanente Northern California during the 2023–2024 respiratory syncytial virus (RSV)-season, researchers found nirsevimab demonstrated high effectiveness in preventing RSV-associated lower respiratory tract disease (LRTD), as published in Pediatrics. Among immunized infants (49.1%), the incidence of RSV-associated LRTD was 6.10 per 1,000 person-years compared to 58.51 in non-immunized infants (95% confidence interval [CI], 81.7%–91.1%; P<0.001). Effectiveness against hospitalized RSV LRTD was 98.0% (95% CI, 85.1%–99.7%). Immunized …

New RSV Vaccine Approved For Infants

The Food and Drug Administration this month approved a new vaccine for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants, designed as preventive care for their first RSV season. The long-acting monoclonal antibody clesrovimab-cfor offers protection through 5 months with the same 105 mg dose regardless of weight, according to a press release from manufacturer Merck. Clinical data from multiple trials shows significant reductions in RSV incidence and …

All Adults Over 75 Should Get RSV Vaccine: CDC

The Centers for Disease Control and Prevention (CDC) recently updated vaccine guidance after its advisory committee recommended that all adults aged 75 years and older and adults aged 60–74 years who are at increased risk should receive a single dose of a respiratory syncytial virus (RSV) vaccine. The update reflects CDC’s intent to maximize RSV vaccination coverage among those most likely to benefit and to reduce implementation barriers associated with a previous recommendation that called …

Login to JUCM